Knockdown of survivin contributes to antitumor activity in cisplatin-resistant ovarian cancer cells

By        

Molecular Medicine Reports, Vol. 7, Iss. 2, 2013-01 ,pp. : 425-430

Spandidos Publications

Access to resources Recommend Favorite

Metformin combined with p38 MAPK inhibitor improves cisplatin sensitivity in cisplatinresistant ovarian cancer

By            

Molecular Medicine Reports, Vol. 10, Iss. 5, 2014-01 ,pp. : 2346-2350

Spandidos Publications

Access to resources Recommend Favorite

Liposomal honokiol, a promising agent for treatment of cisplatin-resistant human ovarian cancer

By Luo Hong  

Journal of Cancer Research and Clinical Oncology, Vol. 134, Iss. 9, 2008-09 ,pp. : 937-945

Springer Publishing Company

Access to resources Recommend Favorite

Inhibition of the p38 MAPK pathway sensitizes human gastric cells to doxorubicin treatment in vitro and in vivo

By  

Molecular Medicine Reports, Vol. 10, Iss. 6, 2014-01 ,pp. : 3275-3281

Spandidos Publications

Access to resources Recommend Favorite

Altered microRNA expression in cisplatin-resistant ovarian cancer cells and upregulation of miR-130a associated with MDR1/P-glycoprotein-mediated drug resistance

By Yang Lingyun   Li Ningwei   Wang Hongjing   Jia Xibiao   Wang Xue   Luo Juan  

Oncology Reports, Vol. 28, Iss. 2, 2012-08 ,pp. : 592-600

Spandidos Publications

Access to resources Recommend Favorite